Report Scope:
The scope of this study encompasses an investigation of cell and gene therapy manufacturing services. The key player analyzes the manufacturing services based on therapy type, application, disease, and end user. The key player determines the current market status in each segment, examines its impact on future markets, and presents growth forecasts over the next six years. The recent report provides a detailed analysis of the market’s drivers, challenges, and opportunities. The report also covers market projections to 2028 and market share for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides the ESG perspective, emerging technologies, and investment outlook.

Report Includes:

  • 34 data tables and 18 additional tables
  • An overview of the global cell and gene therapy manufacturing services market
  • Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Highlights of the market potential and quantification of market based on therapy type, application, disease, and end-user
  • A look into current technologies underlying the market as well as the effects new technologies will have on the market
  • Coverage of clinical trials pipeline, partnership between pharmaceutical companies, and Contract Development & Manufacturing Organization (CDMO)
  • Insights into investments from multiple stakeholders, and discussion on increasing focus on personalized medicine for rare and chronic conditions
  • Information on recent mergers, acquisitions, collaborations, agreements, product launches, and expansions in the market and a relevant patent analysis
  • Company profiles of major players within the industry, including Catalent, Charles River Laboratories, Lonza, Merck KGaA, and Thermo Fisher Scientific